Peroxisome Proliferator-Activated Receptor-Gamma Agonists, Rheumatoid Arthritis and Cardiovascular Disease

Trial Profile

Peroxisome Proliferator-Activated Receptor-Gamma Agonists, Rheumatoid Arthritis and Cardiovascular Disease

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Feb 2017

At a glance

  • Drugs Pioglitazone (Primary)
  • Indications Atherosclerosis; Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms RAPPAR
  • Most Recent Events

    • 28 Oct 2013 Results presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 28 Oct 2013 Primary endpoint 'Flow-mediated-dilation' has not been met.
    • 28 Oct 2013 Primary endpoint 'Pulse-wave-velocity' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top